ABUS vs. ARMP

Last updated Apr 1, 2026

Compare and contrast key facts about Arbutus Biopharma Corporation (ABUS) and Armata Pharmaceuticals Inc. (ARMP).

Performance

ABUS vs. ARMP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Arbutus Biopharma Corporation (ABUS) and Armata Pharmaceuticals Inc. (ARMP). The values are adjusted to include any dividend payments, if applicable.

ABUS vs. ARMP - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
ABUS Arbutus Biopharma Corporation	-6.44%	47.09%	30.80%	7.30%	-40.10%	9.58%	27.70%	-27.42%	-24.16%	106.12%
ARMP Armata Pharmaceuticals Inc.	63.06%	239.46%	-42.90%	161.29%	-77.37%	83.59%	-8.16%	12.53%	-79.57%	-77.05%

Fundamentals

Market Cap ABUS : $862.20M ARMP : $371.09M
EPS ABUS : -$0.17 ARMP : -$4.80
PS Ratio ABUS : 61.33 ARMP : 57.24
Total Revenue (TTM) ABUS : $14.08M ARMP : $6.48M
Gross Profit (TTM) ABUS : $400.00K ARMP : $5.00M
EBITDA (TTM) ABUS : -$38.16M ARMP : -$58.74M

Returns By Period

In the year-to-date period, ABUS achieves a -6.44% return, which is significantly lower than ARMP's 63.06% return. Over the past 10 years, ABUS has outperformed ARMP with an annualized return of 0.76%, while ARMP has yielded a comparatively lower -32.31% annualized return.

ABUS

• 1D: 4.65%
• 1M: -3.43%
• YTD: -6.44%
• 6M: -0.88%
• 1Y: 28.94%
• 3Y*: 14.09%
• 5Y*: 5.58%
• 10Y*: 0.76%

ARMP

• 1D: 19.21%
• 1M: -4.83%
• YTD: 63.06%
• 6M: 243.62%
• 1Y: 601.37%
• 3Y*: 83.03%
• 5Y*: 16.66%
• 10Y*: -32.31%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

ABUS vs. ARMP — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ABUS

ABUS Risk / Return Rank: 62
ABUS Sharpe Ratio Rank: 63
ABUS Sortino Ratio Rank: 58
ABUS Omega Ratio Rank: 57
ABUS Calmar Ratio Rank: 65
ABUS Martin Ratio Rank: 67

ARMP

ARMP Risk / Return Rank: 98
ARMP Sharpe Ratio Rank: 98
ARMP Sortino Ratio Rank: 98
ARMP Omega Ratio Rank: 97
ARMP Calmar Ratio Rank: 99
ARMP Martin Ratio Rank: 99

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ABUS vs. ARMP - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Arbutus Biopharma Corporation (ABUS) and Armata Pharmaceuticals Inc. (ARMP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ABUS	ARMP	Difference
Sharpe ratio Return per unit of total volatility	0.60	3.79	-3.19
Sortino ratio Return per unit of downside risk	1.09	4.73	-3.63
Omega ratio Gain probability vs. loss probability	1.14	1.60	-0.46
Calmar ratio Return relative to maximum drawdown	1.10	14.39	-13.29
Martin ratio Return relative to average drawdown	2.90	38.08	-35.18
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ABUS vs. ARMP - Sharpe Ratio Comparison

The current ABUS Sharpe Ratio is 0.60, which is lower than the ARMP Sharpe Ratio of 3.79. The chart below compares the historical Sharpe Ratios of ABUS and ARMP, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	ABUS	ARMP	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.60	3.79	-3.19
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.10	0.15	-0.05
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.01	-0.29	+0.30
Sharpe Ratio (All Time) Calculated using the full available price history	-0.09	-0.23	+0.14

Correlation

The correlation between ABUS and ARMP is 0.06, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

ABUS vs. ARMP - Dividend Comparison

Neither ABUS nor ARMP has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

ABUS vs. ARMP - Drawdown Comparison

The maximum ABUS drawdown since its inception was -92.96%, smaller than the maximum ARMP drawdown of -99.98%. Use the drawdown chart below to compare losses from any high point for ABUS and ARMP.

Drawdown Indicators

	ABUS	ARMP	Difference
Max Drawdown Largest peak-to-trough decline	-92.96%	-99.98%	+7.02%
Max Drawdown (1Y) Largest decline over 1 year	-25.86%	-37.22%	+11.36%
Max Drawdown (5Y) Largest decline over 5 years	-63.42%	-85.70%	+22.28%
Max Drawdown (10Y) Largest decline over 10 years	-92.96%	-99.84%	+6.88%
Current Drawdown Current decline from peak	-63.56%	-99.79%	+36.23%
Average Drawdown Average peak-to-trough decline	-68.84%	-82.58%	+13.74%
Ulcer Index Depth and duration of drawdowns from previous peaks	9.87%	14.40%	-4.53%

Volatility

ABUS vs. ARMP - Volatility Comparison

The current volatility for Arbutus Biopharma Corporation (ABUS) is 15.46%, while Armata Pharmaceuticals Inc. (ARMP) has a volatility of 32.05%. This indicates that ABUS experiences smaller price fluctuations and is considered to be less risky than ARMP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ABUS	ARMP	Difference
Volatility (1M) Calculated over the trailing 1-month period	15.46%	32.05%	-16.59%
Volatility (6M) Calculated over the trailing 6-month period	36.75%	104.47%	-67.72%
Volatility (1Y) Calculated over the trailing 1-year period	48.45%	160.36%	-111.91%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	55.58%	112.19%	-56.61%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	85.72%	112.45%	-26.73%

Financials